On March 1, it was learned from the Beijing Stock Exchange that 86 Companies on the Beijing Stock Exchange had completed the disclosure of performance express reports at the end of February. With the exception of the biopharmaceutical company Northland, 85 other companies achieved profitability, with a profitability rate of 99%. The People's Daily Health Client found through the data of the Digging Bei Research Institute that among the 8 pharmaceutical manufacturing industries listed on the Beijing Stock Exchange, 5 had a total operating income of more than 300 million yuan, including Senxuan Pharmaceutical (564 million yuan), ZiyuanGong (424 million yuan), Deyuan Pharmaceutical (514 million yuan), Biovalley (566 million yuan), and Yongshun Biology (365 million yuan).
Beijing Daily reporter Dai Bing photographed
As one of the companies with a total revenue of more than 100 million yuan in the pharmaceutical manufacturing industry of the Beijing Stock Exchange, the annual performance express data of the 2021 annual performance report shows that the company's revenue and net profit have doubled, with a net profit of 83.31 million yuan, with a growth rate of 11.17%.
Bio Valley said that the company's total operating income and net profit attributable to shareholders of listed companies have increased, mainly because in addition to market development and channel construction, a series of professional brand publicity activities have been actively and effectively carried out, which has also become the reason for the increase in the company's revenue indicators.
As can be seen from the announcement, only Northland has a net profit loss attributable to the mother. It is reported that Beijing Northland Biotechnology Co., Ltd. is a research and development-oriented high-tech enterprise focusing on the development of therapeutic biological products. The main business is the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs. Northland released the 2021 annual performance express report announcement on February 25, achieving operating income of 57.75 million yuan last year, an increase of 39.36% year-on-year; loss of 51.75 million yuan. For the reasons for the loss, the company said that the company is in the research and development stage, and the R&D investment in 2021 is more, and the research project has not yet achieved commercial sales.
It is worth mentioning that although Northland has a profit loss, the fundraising project "Phase II.A clinical trial for the treatment of acute myocardial infarction ischemia and reperfusion injury indications for acute myocardial infarction with recombinant human thymosin β4 for injection" has been completed. The company announced in January that the project has obtained preliminary research results and is actively preparing for the follow-up Phase II .b clinical trial. ( Zhu Xiaona)
